Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Depreciation & Amortization (CF) (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 7.39% year-over-year to $1.3 million, compared with a TTM value of $5.2 million through Dec 2025, down 8.42%, and an annual FY2025 reading of $5.2 million, down 8.42% over the prior year.
  • Depreciation & Amortization (CF) was $1.3 million for Q4 2025 at Agios Pharmaceuticals, down from $1.4 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.5 million in Q1 2021 and bottomed at $1.3 million in Q2 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $1.8 million, with a median of $1.7 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) fell 27.76% in 2023, then rose 2.16% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $2.2 million in 2021, then decreased by 17.62% to $1.8 million in 2022, then dropped by 22.66% to $1.4 million in 2023, then fell by 2.57% to $1.4 million in 2024, then dropped by 7.39% to $1.3 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for AGIO at $1.3 million in Q4 2025, $1.4 million in Q3 2025, and $1.3 million in Q2 2025.